Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~- Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year at the time of the screening visit insufficiently controlled with basal insulin± metformin.~Exclusion criteria:~At screening:~* Age \< legal age of adulthood.~* HbA1c\<7% or \>10.5%.~* Basal insulin treatment has not been at a stable regimen for at least 3 months and at a stable dose (± 20%) of at least 15 U/day for at least 2 months prior to screening visit.~* If metformin is given, metformin treatment has not been at a stable dose of at least 1.0 g/day for at least 3 months prior to screening visit.~* History of hypoglycemia unawareness.~* Body Mass Index (BMI) ≤20 kg/m².~* Use of other oral or injectable glucose-lowering agents other than basal insulin or metformin within 3 months prior to the time of screening.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lixisenatide (Type: EXPERIMENTAL): 24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
- Placebo (Type: PLACEBO_COMPARATOR): 24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).